← Eichor
Study identifier: NCT06877793 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Real-Time Diagnosis of Life-Threatening Necrotizing Soft Tissue Infections (NSTI) Using Indocyanine Green (ICG) Kinetic Modeling

Condition: Necrotizing Fascitis  ·  Sponsor: Eric R. Henderson

PhaseN/A
Planned participants420
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Necrotizing soft-tissue infections (NSTIs, a.k.a. "necrotizing fasciitis" or "flesh-eating bacteria") are aggressive infections that can progress rapidly from mild symptoms to sepsis, multi-organ failure, and death. NSTI cases present with non-specific clinical, imaging, and laboratory findings, and standard-of-care techniques for NSTI diagnosis lack sensitivity and specificity, resulting in frequent misdiagnosis and delayed care, which is the single most important predictor of survival. Consequently, the cumulative mortality rate for patients with NSTIs is 20- 30%; a dire need exists for more accurate and rapid detection of NSTIs. Fluorescence-guided surgery is a nascent technology seeking to improve the recognition of anatomical structures and disease processes using fluorescent probes (fluorophores). Indocyanine green (ICG) is an FDA-approved, near-infrared fluorophore with a \>60-year safety record for vascular perfusion assessment. A distinguishing histological feature of NSTIs is prominent blood vessel thrombosis in affected tissues. Leveraging these pro-thrombotic effects, our study group has demonstrated in a first-in-human study (NCT04839302) that intravenous administration of ICG and immediate fluorescence imaging reveals prominent signal deficits in NSTI-positive tissues that differentiate significantly with increased signal seen with more common-and less virulent-infections such as cellulitis. We seek now to evaluate this imaging technique on a broader scale and d…

This description comes directly from the study's public registry record.

Talk to the study team

Eric R Henderson, MD  ·  603-650-5133  ·  Eric.R.Henderson@hitchcock.org

Morgan T Mazanec, MPH  ·  603-308-9233  ·  Morgan.T.Mazanec@Hitchcock.ORG

Always discuss trial participation with your own doctor first.

Locations (8)

University of California, Los AngelesLos Angeles, California, United StatesNot Yet Recruiting
Stanford UniversityStanford, California, United StatesRecruiting
Emory University/Grady Memorial HospitalAtlanta, Georgia, United StatesRecruiting
University of MichiganAnn Arbor, Michigan, United StatesRecruiting
Dartmouth-Hitchcock Medical CenterLebanon, New Hampshire, United StatesRecruiting
University of PennsylvaniaPhiladelphia, Pennsylvania, United StatesRecruiting
University of Pittsburgh Medical CenterPittsburgh, Pennsylvania, United StatesNot Yet Recruiting
Vanderbilt UniversityNashville, Tennessee, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06877793